Elicio Therapeutics (ELTX) Return on Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Return on Equity data on file, last reported at 3.86% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 424.0% year-over-year to 3.86%; the trailing twelve-month figure through Mar 2026 stood at 3.86% (down 424.0% YoY), and the FY2025 full-year result was 0.08%, up 1498.0% from the prior year.
• Return on Equity for Q1 2026 stood at 3.86%, down from 0.14% in the prior quarter.
• Across five years, Return on Equity topped out at 0.38% in Q1 2025 and bottomed at 3.86% in Q1 2026.
• The 5-year median for Return on Equity is 0.0% (2022), against an average of 0.24%.
• The widest annual swing landed in 2022, when Return on Equity surged 63 bps; it then slumped 424 bps in 2026.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then plunged by 944 bps to 0.03% in 2023, then jumped by 200 bps to 0.03% in 2024, then plunged by 573 bps to 0.14% in 2025, then plunged by 2650 bps to 3.86% in 2026.
• The last three Return on Equity figures came in at 3.86% (Q1 2026), 0.14% (Q4 2025), and 0.15% (Q3 2025), per Business Quant data.

Peer Comparison